Asymptote introduces the my.Cryochain software platform to control the cryogenic cold chain for cellular therapies

Enables standardisation and audit of remote freezing and thawing

Asymptote Ltd., specialists in cryochain technology for advanced medicines, today announced the commercial launch of my.Cryochain, a software platform developed specifically to give centralised control of the cryogenic cold chain for cellular therapies.

 

As production of cellular therapies scales from clinical trials to market authorisation and beyond, manufacturing companies and research groups face multiple challenges. These include maintaining consistency in freezing and thawing across multiple sites, and auditing remote processes, particularly at the thawing stage. Asymptote developed my.Cryochain to provide a reliable and scalable solution which can support Good Manufacturing Practice (GMP).

 

The new software synchronises with Asymptote’s VIA Freeze range and soon-to-be released automated thawing systems. Authorised users then have centralised control over the freezing and thawing of cells; critical to the delivery of cell and gene therapies. Optimal freeze/thaw profiles can be customised in the central system during process qualification. Once approved, they are synchronised across all connected equipment, to remove variability and standardise processes.

 

my.Cryochain automatically manages profile versions to support continuous improvement. When a process enhancement is identified, the history of all changes is automatically recorded and the new profile is re-synchronised to all equipment in the field.

 

The my.Cryochain platform enables users to record, annotate and audit cryopreservation processes electronically. The system provides instant and remote access to data from every VIA Freeze and automated thawing system, thereby saving scientists’ time and increasing efficiency. A full electronic audit trail also enables scientists to more easily identify anomalies and document observations. All data is automatically stored in the central system, where it can be backed up and protected for five years or more.

 

my.Cryochain has been developed as a scalable system to suit every stage of clinical development, from early clinical trials and investigational work to mass production and delivery, with thousands of connected VIA Freeze units and automated thawing systems across multiple continents.

We have developed my.Cryochain to enable cell therapy companies and scientists to have centralised control over freezing and thawing of cellular therapies  

Commenting on the commercial launch of my.Cryochain, John Morris, CEO, Asymptote said: “We have developed my.Cryochain to enable cell therapy companies and scientists to have centralised control over freezing and thawing of cellular therapies. The ability to define freeze/thaw profiles centrally during process qualification and synchronise these to their VIA Freeze units and automated thawing systems enables processes to be standardised across all sites. Real-time and sustained access to data from the equipment, allows remote processes to be audited and improvements made swiftly. For the first time, manufacturers and scientists will have control of the end-to-end cryogenic cold chain.”

Companies